Aviado · Research
Longevity Daily
Saturday, October 17, 2026
Listen
Today's Brief
Today's sharpest finding: Monash University data shows low-dose aspirin may cut dementia risk by 70% in genetically susceptible older adults — but a concurrent bleeding risk means this isn't a universal recommendation. The LifeAfter90 study adds to the cognitive picture, confirming APOE ε4 accelerates executive function decline even in nonagenarians. DO-HEALTH2 research meanwhile shows that omega-3, vitamin D, and exercise together measurably slow biological aging clocks — a win for the supplement-plus-lifestyle crowd. Our Aviado analysis on sulforaphane rounds out the issue with one of the field's most quantifiable detox stories.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Aspirin May Cut Dementia Risk by 70% — But Only If You Have the Right Genetic Profile
A Monash University analysis found older adults with a specific genetic variant had roughly 70% lower relative risk of developing dementia when taking low-dose aspirin — a striking finding that could reshape how we think about preventive therapy for Alzheimer's. The catch: the same genetic group also experienced higher rates of serious bleeding, the side effect that ended earlier aspirin-for-everyone trials. This isn't a signal to start aspirin without medical guidance, but it is a clear argument for genetic testing before ruling it out entirely. If you carry that variant, this finding is worth a conversation with your doctor.
Read more →APOE ε4's Grip on Cognitive Decline Persists Even in People Who Reach Their 90s
The LifeAfter90 study tracked 445 multiethnic adults aged 90 to 104 across up to 11 testing sessions and found APOE ε4 carriers still experienced significantly faster executive function decline than non-carriers — even at exceptional ages. The protective APOE ε2 variant showed a meaningful benefit for verbal episodic memory in this oldest-old group. For the roughly 20% of the population carrying at least one ε4 allele, reaching 90 doesn't erase the risk — it means staying vigilant about cognitive health for longer.
Read more →Supplements & Compounds
Omega-3, Vitamin D, and Exercise Together Slow Biological Aging on DNA Methylation Clocks
DO-HEALTH2 research found that combining omega-3 fatty acids with vitamin D supplementation and regular exercise slowed aging as measured by DNA methylation clocks — the epigenetic markers used in biological age testing. Critically, no single intervention achieved the effect; it was the combination that moved the needle. This is one of the cleaner human trials supporting a supplement-plus-lifestyle approach, and it aligns what longevity-minded consumers are already doing with actual measurable outcomes.
Read more →Only 1 in 10 Supplements Sold at Army Bases Meets the Pentagon's Own Safety Standards
A study published in Military Medicine found that just 10% of dietary supplements sold at two Army bases carried the third-party certification recommended by the Department of Defense — meaning 90% of what's on the shelves hasn't been independently verified for purity, potency, or label accuracy. This isn't just a military problem; the same unverified products fill civilian shelves everywhere. Before buying any supplement, look for NSF Certified for Sport, USP Verified, or Informed Sport certification — it's the only way to confirm what's actually in the bottle.
Read more →Sulforaphane Doesn't Just "Detox" — It Eliminates Specific Pollutants by Up to 61%
Unlike vague detox claims, sulforaphane from broccoli sprouts has quantifiable results: human studies show it increases urinary excretion of benzene and acrolein — common urban and industrial pollutants — by 23–61%, by activating Nrf2, the master switch for your liver's detoxification enzymes. The key is choosing extracts standardized for 30–60 mg sulforaphane daily, ideally combining glucoraphanin with active myrosinase to maximize conversion and bioavailability. Our full analysis breaks down the mechanism, the human evidence, and exactly what to look for on a label.
Read the full Aviado analysis →Research & Papers
Why Large Dogs Age Faster: Epigenetic Study Pinpoints Transposable Elements as a Key Culprit
Researchers found that larger dog breeds — which live shorter lives than smaller ones — show accelerated epigenetic change specifically in regions of DNA containing transposable elements: ancient viral remnants that can disrupt gene sequences and trigger inflammation when activated. The finding suggests transposable element activation may be a meaningful and underappreciated driver of mammalian aging more broadly. This adds mechanistic weight to an emerging longevity target — keeping these genomic "parasites" silenced through epigenetic stability.
Read more →The Same Immune Aging Process May Be Driving Both Osteoporosis and Osteoarthritis
Researchers argue that immune aging — driven by accumulation of senescent immune cells and chronic low-grade inflammation — is a shared upstream cause of both bone loss and joint degeneration, rather than two unrelated conditions developing in parallel. This reframing matters because it suggests targeting immune aging could address both conditions simultaneously. Senolytics and anti-inflammatory strategies already in clinical investigation may prove more broadly useful for musculoskeletal aging than previously understood.
Read more →Lifestyle & Nutrition
UK Scientists Call Bryan Johnson's £1.6M Anti-Aging Plan "Flawed" — and Point to a Simpler Fix
A team of UK university scientists has dissected Bryan Johnson's hyper-optimized longevity protocol and concluded the extreme, expensive regime has significant design flaws — while also identifying a simpler dietary strategy, 6:1 intermittent fasting, that achieves meaningful results at a fraction of the cost. The critique isn't that optimization doesn't matter; it's that Johnson's version is poorly designed and financially inaccessible to virtually everyone. For readers already familiar with Blueprint, this is a useful reality check and a prompt to take fasting strategies more seriously.
Read more →Industry & Policy
Eli Lilly's Triple Agonist Retatrutide Hits 30% Average Weight Loss in Pivotal Phase 3 Trial
Eli Lilly's retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — delivered up to 30.3% average body weight reduction in the TRIUMPH-1 Phase 3 trial, setting a new benchmark for pharmacological weight loss that exceeds current semaglutide and tirzepatide results. Additional Phase 3 data from TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (cardiovascular disease) are expected later this year. Given that obesity accelerates nearly every hallmark of aging, this drug class is becoming increasingly central to longevity medicine — not just metabolic disease management.
Read more →What Are Hospital Longevity Clinics Actually Selling? A Closer Look Says: Time and Attention
STAT reporter Sarah Todd's "Selling Longevity" series examined cash-pay programs at Northwestern Medicine, Weill Cornell, and Mayo Clinic — and found the core product isn't cutting-edge diagnostics or advanced therapeutics, but something far more basic: dedicated physician time and personalized attention. The medicine, for the most part, isn't more advanced than what's available through a thorough internist. As the longevity clinic market scales toward a multitrillion-dollar valuation, this is a useful dose of skepticism for anyone considering enrolling.
Read more →